Transcranial Direct Current Stimulation of the Motor Cortex in Essential Tremor
NCT ID: NCT03952117
Last Updated: 2019-08-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
40 participants
INTERVENTIONAL
2019-07-19
2021-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A total of 40 patients ought to be enrolled as specified in methodology. Secondary outcomes will assess TRG essential tremor rating assessment scale (TETRAS) as well as clinical monitoring.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Experimental Therapeutics in Essential Tremor Using Cerebellar Transcranial Direct Current Stimulation
NCT02052271
Trans-spinal Direct Current Stimulation in Primary Orthostatic Tremor
NCT02978924
Effects of High Amplitude and Focused tACS on Entraining Physiological Tremor
NCT03337334
The Trans-cutaneous Effects on Physiological Tremor Entertainment During tACS
NCT04065022
Relief From Side Effects: Clinical Use of Electrodes With Direction
NCT03795935
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The proposed mechanism that underlies ET, the central oscillating network, is mainly composed of the olivocerebellar system, thalamus and motor cortex. An interruption in this circuit limits the ability of the cortex to reorganize and restore ET. a case of 76 year old female with essential tremor that disappeared following a cortico-subcortical prerolandic stroke despite complete motor recovery highlights the role of the motor cortex in the production and possible therapeutic role of the transcranial direct current stimulation.
Study design A randomized, sham-controlled, double blind and crossover study.
Study procedure:
The first visit is an inclusion visit Prior to starting the first tDCS session, the patient will be asked to fill his/her first TRG essential tremor assessment (TETRAS) scale. The physician will then quantitatively analyze the tremor on the most affected side using an accelerometer. Cathodal tDCS will be administered on the area representing the primary motor cortex and the anode over the contralateral supraorbital area. tDCS stimulation (cathodal and sham) will be done daily for 5 consecutive days during weeks 1 and 5. Each stimulation session will last 30 minutes. tDCS will be performed while the patient is at rest, without any concurrent cognitive or motor task.The two tDCS sessions will be separated by a 23 day washout period.
Patient will be asked to fill out their TETRAS at days 1 and 5 of each tDCS session (cathodal and sham), and days 12 and 19 after each tDCS session (cathodal and sham).
Accelerometer assessment of the tremor will be performed at days 1 and 5 of each tDCS stimulation session (cathodal and sham).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active tDCs
Active tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator. The cathode will be positioned facing the primary motor cortex area and the anode over the contralateral supraorbital area.
transcranial direct current stimulation
tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
Sham tDCS
Sham stimulation will be delivered to the motor cortex using a sham tDCS device that delivers a direct current for 10 seconds at the beginning and end of tDCS to provide sensory experiences similar to active stimulation.
transcranial direct current stimulation
tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
transcranial direct current stimulation
tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Orthostatic tremor with a frequency of more than 12 Hz
* Task and position specific tremor
* Sudden onset and stepwise deterioration of tremor
* History of substance abuse or dependence in the past
* Co-morbid medical conditions capable of producing or enhancing tremors
* Use of a medication with potential effect on tremor
* History of neurological disorders, brain tumors, brain surgery or abnormal neurological examination
* Epileptic disorders
* Cardiac pacemakers
* Metallic hardware in the head or scalp (surgical clips)
* Eczema or skin abrasion at the intended site of stimulation
* Currently pregnant or plan for pregnancy in the next 6 months
* Patients with prior experience with tDCS
* Major psychosocial problems or medical problems rendering informed consent impossible
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lebanese American University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rechdi Ahdab
M.D , PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rechdi Ahdab
Role: PRINCIPAL_INVESTIGATOR
Lebanese American University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
LAUMCRH
Beirut, , Lebanon
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LAUMCRH.RA3.11/Apr/2019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.